News

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
BioSpace16h

Ionis Wins Approval For First RNA-Targeted Prophylactic for Rare Swelling Disease

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...
TipRanks on MSN18h

Ionis Pharmaceuticals price target raised to $70 from $65 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps a Buy rating on the shares following FDA ...
Stocktwits on MSN1d

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

Wall Street analysts boosted their targets on Ionis Pharmaceuticals after the FDA approved its RNA-based drug Dawnzera for hereditary angioedema, sparking a surge in retail chatter. BofA Securities ...

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.
TipRanks on MSN18h

Ionis Pharmaceuticals price target raised to $65 from $62 at Piper Sandler

Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $62 and keeps an Overweight rating on the shares ...
Hosted on MSN1d

Ionis Pharmaceuticals trading halted, news pending

09:38 EDT Ionis Pharmaceuticals (IONS) trading halted, news pending Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...